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Myosin Va is a well known processive motor involved in transport of
organelles. A tail-inhibition model is generally accepted for the
regulation of myosin Va: inhibited myosin Va is in a folded confor-
mation such that the tail domain interacts with and inhibits myosin Va
motor activity. Recent studies indicate that it is the C-terminal glob-
ular tail domain (GTD) that directly inhibits the motor activity of
myosin Va. In the present study, we identified a conserved acidic
residue in the motor domain (Asp-136) and two conserved basic
residues in the GTD (Lys-1706 and Lys-1779) as critical residues for this
regulation. Alanine mutations of these conserved charged residues
not only abolished the inhibition of motor activity by the GTD but also
prevented myosin Va from forming a folded conformation. We
propose that Asp-136 forms ionic interactions with Lys-1706 and
Lys-1779. This assignment locates the GTD-binding site in a pocket of
the motor domain, formed by the N-terminal domain, converter, and
the calmodulin in the first IQ motif. We propose that binding of the
GTD to the motor domain prevents the movement of the converter/
lever arm during ATP hydrolysis cycle, thus inhibiting the chemical
cycle of the motor domain.
actin  trafficking  molecular motor  lever arm  regulation
It is generally accepted that motor protein activity must be tightlyregulated in cells to transport cargo efficiently and to prevent the
futile hydrolysis of ATP. One of the best characterized regulations
of myosin motor proteins is the regulation of vertebrate myosin Va.
Myosin Va consists of two identical heavy chains that
dimerize through the formation of a coiled-coil structure to
form a homodimer. At the amino terminus is the motor
domain containing ATP- and actin-binding sites. The motor
domain is followed by a neck that consists of six IQ motifs with
the consensus sequence IQXXXRGXXXR, which act as the
binding sites for calmodulin (CaM) or CaM-like light chains.
The next 500 aa are predicted to form a series of coiled-coils
separated by several f lexible regions. The last 400 aa form a
C-terminal globular tail domain (GTD). The GTD, in con-
junction with a portion of the coiled-coil region, mediates
myosin Va binding to specific membrane-bounded organelles,
such as melanosomes (1–4).
Significant progress has recently been achieved in understanding
the mechanism of myosin Va regulation, although it was shown as
early as 1993 that the actin-activated ATPase activity of myosin Va
purified from chick brain is well regulated by Ca2 (5). It was found
that Ca2-activation of the ATPase activity of myosin-Va is ac-
companied by a large conformational transition, from a 14S folded
conformation in the absence of Ca2 to an 11S open conformation
in the presence of micromolar Ca2 (6–8). In contrast, myosin Va
heavymeromyosin (HMM), a constitutively active fragment lacking
the C-terminal globular tail domain, is not well regulated by Ca2
and does not undergo a large conformational transition like full-
length myosin Va (6–8). These results suggest that the tail domain
plays a key role in the Ca2-dependent regulation of myosin Va by
inhibiting the ATPase of the head. Based on these findings, a
tail-inhibition model for the regulation of myosin Va has been
proposed (6–8). In this model, myosin Va in the inhibited state is
in a folded conformation such that the tail domain interacts with
and inhibits myosin Va motor activity; high Ca2 or cargo binding
may reduce the interaction between the head and tail domains, thus
activating motor activity.
Using negative staining electron microscopy, Knight and col-
leagues first observed a triangular shape of myosin Va in the
absence of Ca2 but not in its presence: The head domains
apparently fold back to interact with the tail domain (7). Later, it
was found that the GTD directly inhibits the activity of the motor
domain of myosin-Va: Myosin-Va HMM is inhibited and folded by
exogenous GTD (9, 10). We found that strong inhibition of motor
activity by theGTD requires not only the two-headed structure, but
also the presence of an intact first long coiled-coil segment of the
tail (9). Based on these findings, we proposed that the GTD
simultaneously binds to the motor domain and the C terminus of
the first long coiled-coil segment of the tail, thus forming a
triangular conformation (9). However, the precise interaction be-
tween the GTD and the motor domain and thus the mechanism of
inhibition remained unclear.
Based on averaged images of inhibited myosin Va and molecular
modeling, Knight and colleagues proposed that the GTD binds to
a lobe of the motor domain (P117-P137) that contains several
conserved acidic residues (10). Because the assigned GTD-binding
site has no direct interaction with the ATP-binding site, they
proposed that the GTD regulates motor activity allosterically (10).
However, Taylor and colleagues assigned the GTD-binding site to
loop 1, which is near the entrance of the ATP-binding pocket in the
motor domain (11). They proposed that binding of theGTD to loop
1 decreases the rates of nucleotide exchange, thus inhibiting the
ATPase activity of the motor domain (11). However, the recently
solved crystal structure of the motor domain of chicken myosin Va
(12, 13) and the GTD of Myo2p, a yeast myosin V (14), show that
it is unlikely that the GTD binds to lobe P117-P137 and loop-1
simultaneously.
In this study, we identify a conserved acidic residue (D136) in
lobe P117-P137 in the motor domain and two conserved basic
residues (K1706 and K1779) in the GTD as critical residues for the
inhibition of myosin Va. Based on these findings, we propose a
model for inhibition of the motor domain by the GTD.
Results
The Conserved Residue D136 in the Motor Domain of Class V Myosin
Is Responsible for the Inhibition of Myosin Va ATPase Activity by the
GTD. It was proposed that the GTD binds to lobe P117–P137 in the
motor domain of mouse myosin Va to inhibit its ATPase activity
(10). Among the four acidic residues in lobe P117-P137, two acidic
residues, D134 and D136, are highly conserved in class V myosins
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but not in other classes. To investigate the role of these two acidic
residues on the regulation of myosin Va, we examined the effect of
D134A and/or D136A mutations on the inhibition of the actin-
activated ATPase activity of myosin Va by the GTD.
Previously, we showed that the exogenous GTD is capable of
inhibiting the actin-activated ATPase activity of myosin-Va heavy
meromyosin (M5HMM) in a Ca2-dependent manner (9). As
shown in Fig. 1, GST-GTD strongly inhibited the actin-activated
ATPase activity of M5HMM-WT and -D134A, but it failed to
inhibit these of D134A/D136A and D136A mutants. Whereas
D134A mutation decreased the affinity between GST-GTD and
M5HMM fivefold, the ATPase activity of the D134A mutant was
still strongly inhibited by GST-GTD. These results indicate that
D136 is essential for the inhibition of myosin Va motor function by
the GTD.
The Conserved Residue D136 in the Motor Domain of Class V Myosin
Is Critical for the Folded Conformation of Myosin Va. To further
determine the role of D134 and D136 on the regulation of myosin
Va, we introduced D134A and D136A mutations individually in
full-length mouse myosin Va (M5Full). Consistent with previous
reports (5–8), we found that the actin-activated ATPase activity of
M5Full-WT was well regulated by Ca2; i.e., it had a low actin-
activated ATPase activity in the absence of Ca2 (EGTA condi-
tions) and highATPase activity in the presence ofCa2 [Fig. 2A and
supporting information (SI) Table 1]. High Ca2 enhanced the
ATPase activity of myosin Va by 10-fold. Similar to that of WT,
the actin-activated ATPase activity of M5Full-D134A was signifi-
cantly inhibited in EGTA (Fig. 2B and SI Table 1). In contrast, we
found that the actin-activated ATPase activity ofM5Full-D136A in
EGTA was markedly increased compared with that of WT under
the same conditions, and Ca2 only slightly enhanced its ATPase
activity (Fig. 2C and SI Table 1). The ATPase activity of M5Full-
D136A in the absence of Ca2was similar to a truncatedmyosinVa
without the GTD (8). These results indicate that the EGTA-
induced inhibition of myosin Va was strongly dampened by D136A
mutation, suggesting the importance of this residues for the
regulation.
It has been shown that the activation of myosin Va by Ca2 is
accompanied by a transition froma folded conformation (14S in the
absence of Ca2) to an open conformations (11S in the presence of
Ca2) (6–8). We took two approaches to investigate the effect of
D134A and D136A mutations on the conformational changes
of myosin Va.
First, we used negative staining electron microscopy to visualize
the conformation of M5Full. We found that the majority of
M5Full-WT and -D134A molecules were in the folded conforma-
tion in EGTA (Fig. 3 A and B). In contrast, M5Full-D136A
molecules were in the open conformation in the same conditions
(Fig. 3C).
Second, we performed an analytical ultracentrifuge analysis.
Similar to those of WT (6), the sedimentation coefficient (s value)
of theM5Full-D134Adecreased from 14.3S in EGTA conditions to
11.3S in pCa4 conditions (Fig. 4A). In contrast, M5Full-D136A
underwent only a small change in the s value, from 10.7S in EGTA
conditions to 11.3S in pCa4 conditions (Fig. 4B). Note that the
direction of this change is opposite to those for the WT (6) and
D134A. In pCa4 conditions, the s values of both mutants are
essentially identical to that of the WT (6), which is in the open
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Fig. 1. Inhibition of the actin-activated ATPase activity of M5HMM with
D134A and/or D136A mutations by GST-GTD. The dissociation constants (Kd) of
GST-GTD and M5HMM, obtained by a quadratic fit, are 0.058 M (M5HMM-
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Fig. 2. Effect of D134A, D136A, and K1706A/K1779A mutations on the regulation of the actin-activated ATPase activity of M5Full. (A) WT. (B) D134A. (C) D136A.
(D) K1706A/K1779A. Data were fit with a hyperbola to define Vmax (maximal ATPase activity) and Kactin (the concentration of actin that stimulates the ATPase
activity to 50% of Vmax). SI Table 1 summarizes the Vmax and Km values for multiple assays.
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conformation, indicating that both mutants are in the open con-
formation in pCa4 conditions. The s value of M5Full-D136A in
EGTA conditions is lower than in pCa4 conditions, suggesting that
the conformation of the M5Full-D136A is more open in EGTA
conditions than in pCa4 conditions. Taken together, these results
show that D136 in the motor domain plays a critical role in the
inhibition of the ATPase activity by theGTD and in the production
of the folded conformation of myosin Va.
Two Conserved Basic Residues in the GTD Are Responsible for the
Inhibition of Myosin Va. It is known that that the folded conforma-
tion of myosin Va is very sensitive to ionic strength (6–8), suggest-
ing that the head-tail interaction is mediated by electrostatic
interaction. In the motor domain of myosin Va, we have identified
a conserved acidic residue, D136, responsible for the inhibition of
the motor function by GTD and a folded conformation. Crystal
structures of the myosin Va motor domain show that the side chain
of D136 protrudes outward (13). Thus, we expect that D136
interacts with a basic residue(s) in the GTD.
Knight and colleagues suggested that the acidic residues in lobe
P117–P137 in the motor domain may interact with residues in the
GTD within R1800–K1810, which contains a cluster of five basic
residues (10). The homologous residues of yeast Myo2p are located
in the distal end of the GTD, and well suited to match the
morphology of the inhibitedmyosinVa (14). To determine the roles
of the basic residues within R1800–K1810, we introduced alanine
mutations of these basic residues in the GST-GTD and examined
the effect of these mutations on the regulation. We found that all
of the alanine mutants, including R1800A, R1805A/R1807A,
R1809A, and K1810A, potently inhibited the ATPase activity of
M5HMM, with apparent Kd similar to that of WT GST-GTD (SI
Fig. 7). These results indicate that the basic residues in R1800–
K1810 are not essential for inhibition.
Because the acidic residue D136 is a conserved residue in class
Vmyosins, we hypothesized that the side chain ofD136 in themotor
domain interacts with conserved basic residue(s) in the GTD.
Because the crystal structure of theGTD is known forMyo2p-GTD
(theGTD ofMyo2p, a yeast myosin V), we compared the sequence
of mammalian myosin V (mouse myosin Va, rat myosin Vb, and
human myosin Vc) with that of yeast Myo2p. Ten conserved basic
residues were identified in the GTD (SI Fig. 8). The crystal
structure of the Myo2p-GTD shows that 7 of the 10 are located on
or close to the surface of the GTD; one (K1756) is an internal
residue, and two (R1647 and K1820) are missing in the crystal
structure (SI Fig. 9). We expected that only the conserved basic
residues located on the surface of GTD would be capable of
interacting with the acidic residue in the motor domain and
therefore focused our effort on those residues.
To determine the role of these residues on regulation, we
mutated them into alanine and examined the inhibitory activity of
the GST-GTD mutants. Among nine single alanine mutations,
three, R1705A, K1706A, and K1779A, dramatically decreased the
inhibitory activity of GST-GTD on the M5HMM ATPase activity
(Fig. 5). The Kd of WT GST-GTD for the inhibition of M5HMM
ATPase activity was 0.058M,whereas that of the R1705Amutant
was 3.6 M. The inhibitory activities of the K1706A and K1779A
mutants were very weak, and thesemutants could inhibit activity no
more than 30%, even at the highest concentration tested (8 M).
In the crystal structure of Myo2p-GTD, R1705, K1706, and K1779
are located in a cluster in contrast to other conserved basic residues
in the GTD (SI Fig. 9). The side chain of R1705 faces inward, but
those of K1706 and K1779 protrude outwards, suggesting that both
side chains of K1706 andK1779may interact with the acidic residue
of D136.
We thought that the weak inhibitory activity of K1706A and
K1779A might come from interaction between the remaining
basic residue, i.e., K1779 or K1706, respectively, in these GTD
mutants and D136 in the motor domain. If so, eliminating both
basic residues should completely eliminate the inhibitory activity
of the GTD. Indeed, K1706A/K1779A mutations completely
eliminated inhibitory activity of the GTD (Fig. 5K).
Two Conserved Basic Residues in the GTD Are Responsible for the
Folded Conformation of Myosin Va. Because K1706A/K1779A mu-
tations abolished the inhibition ofM5HMMATPase activity by the
A B
C D
Fig. 3. Effect of D134A, D136A, and K1706A/K1779A mutations on the
conformation of M5Full. EM Images of negatively stained M5Full in EGTA
conditions. (A) WT. (B) D134A. (C) D136A. (D) K1706A/K1779A. Black arrows
indicate triangular shaped molecules, and white arrows indicate open Y-
shaped molecules. (Scale bars: 100 nm.)
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GTD, we expected that these mutations would dampen the regu-
lation of full-length myosin Va by Ca2. As expected, there was
significant activation of M5Full-KKAA (K1706A/K1779A)
ATPase activity inEGTA(Fig. 2D andSITable 1). This activity was
a little elevated by Ca2.
Because the inhibition of the actin-activated ATPase activity of
myosin Va is correlated with the formation of a folded conforma-
tion (6–8), we expected thatK1706 andK1779would play a key role
in maintaining a folded conformation of myosin Va. Negative
staining electron microscopy revealed that majority of M5Full-
KKAA molecules are in the open conformation even in EGTA
conditions (Fig. 3D). Analytical ultracentrifuge analysis showed
that M5Full-KKAA underwent only a small change from 10.2 S in
EGTA conditions to 11.2 S in pCa4 conditions (Fig. 4C) similar to
that observed for the D136A mutant (Fig. 4B), indicating that
M5Full-KKAA molecules are in an open conformations in both
conditions.
Discussion
Structure of Inhibited Myosin Va. In the present study, we identified
a conserved acidic residue in the motor domain (D136) and two
conserved basic residues in the GTD (K1706 and K1779) as critical
residues for this regulation. Alanine mutations of these conserved
charged residues not only abolished the inhibition of motor activity
by the GTD, but also prevented myosin Va from forming a folded
conformation. Based on these findings, we propose a model for the
interaction between themotor domain and theGTD (Fig. 6). In this
model, an oxygen atom (O) of D136 in the motor domain and a
nitrogen atom (N) of R272 and a nitrogen atom (N) of K343 in
Myo2p-GTD (homolog residues of K1706 and K1779 in mouse
myosin Va, respectively) are within 4 Å of each other, thus
forming ionic bridges. This arrangement puts the GTD in a pocket
of themotor domain, which is formed by theN-terminal, converter,
and CaM/IQ1 domains.
Previously, we and other groups have found that exogenousGTD
potently inhibits ATPase activity of the HMM form of myosin Va
but only weakly inhibits ATPase activity of the S1 form (9, 10),
suggesting that either the formation of the two-headed structure or
the coiled-coil domain contributes to the inhibition by theGTD.We
also found that deletion of the C-terminal residues of the first long
coiled-coil significantly hampers inhibition by the GTD (9). How-
ever, deletion of these residues did not influence the formation of
the two-headed myosin V. Therefore, we proposed that the C-
terminal region of the first coiled-coil of themyosinVa tail is critical
for the formation of a folded conformation and the GTD-induced
inhibition of myosin Va activity (9). We propose the following
scenario for formation of the folded triangular structure. The GTD
domain binds to the C-terminal residues of the first coiled-coil. The
neck–neck joint is flexible enough to allow the head domain to
contact the GTD residing at the C-terminal end of the first
coiled-coil. The acidic side chain of D136 interacts with the
basic side chains of K1706 and K1779, stabilizing the folded
conformation of myosin Va.
The folded triangular conformation of inhibited myosin Va is
common in various nucleotides, including ATP, ADP, and rigor
(6–10). Thus, it is expected that the interactions between the motor
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domain and the GTD are preserved in these conditions. Indeed,
molecular modeling shows that the interactions between D136 in
themotor domain andK1706/K1779 in theGTDcan bemaintained
at least in postrigor (Fig. 6) and prepower stroke conformations (SI
Fig. 10).
Mechanism for Inhibition of the Motor Domain ATPase by the GTD.
The mechanism by which the GTD inhibits the ATPase activity
of themotor domain is not clear. BecauseD136 is2 nmaway from
the ATP-binding site and7 nm away from the actin-binding site,
it is less likely that interaction of the GTD basic residues with D136
directly alters ATP binding or actin binding. Knight and colleagues
proposed that the GTD allosterically regulates the ATPase activity
(10). They suggested two allosteric routes by which binding of the
GTD could perturb ATPase activity. First, the N-terminal part of
P117-P137 interacts with the C-terminal turns of helix F of the
motor domain. At the N terminus of helix F is the P-loop (which is
critical for ATPase activity), which could therefore be sensitive to
GTD binding. Second, the residues upstream of P117, to N111,
form part of the binding sites for the adenine and ribose moieties
of ATP. GTD-binding could thus have a big effect on affinity for
nucleotide. However, the results from this study suggest other
mechanism.
A critical point is that ATP hydrolysis induces a structural change
in the motor domain that is connected to the converter and lever
arm (13, 15–18). The small change in the catalytic ATPase site is
coupled with large conformational changes in the converter and
lever arm. Most consider that the flow of structural change above
is from ATP to the converter/lever arm. However, as pointed out
by Fischer et al. (19), the coupling mechanism is also valid in the
reverse direction, i.e., a motion in the converter (and lever arm) can
lead to corresponding modifications near ATP. Consistently, a
recent study showed the communication from the lever arm to the
ATPase site inDictyosteliummyosin II (20). Comparison of various
structures of the myosin motor has shown that the conformational
changes in themotor domain (with various nucleotides bound) take
place mostly by rigid-body rotations of secondary and tertiary
structure elements (reviewed in ref. 21). Thus, it is likely that
hindering the movements of these structural elements will slow the
ATP turnover rate.
Identification of the GTD-binding site in the motor domain
provides a clue on how the GTD might inhibit motor domain
function. In our model, the GTD-binding site is surrounded by the
N-terminal domain, converter, and CaM/IQ1 domain, which is part
of the neck domain or lever arm. We thus propose a ‘‘brake
mechanism’’ for the inhibition of myosin Va by the GTD: The
binding of theGTD to themotor domain preventsmovement of the
converter/lever armduring theATPhydrolysis cycle, thus inhibiting
the chemical cycle of the motor domain.
In our previous kinetic study of myosin Va ATPase (22), we
found that the basalATPase ofmyosinVa is also regulated byCa2.
Single turnover assay of full-length myosin VaATPase showed that
the rate constant of the predominant fraction of the basal ATPase
in EGTA was 10 times slower than that in Ca2. Thus, the basal
ATPase activity is also inhibited in EGTA, supporting our model
that the GTD-dependent inhibition acts allosterically on the AT-
Pase site by constraining converter/lever arm movement.
We found that the major effect of the formation of the inhibited
structure on the ATP hydrolysis cycle is strong inhibition of
phosphate release (1,000-fold) from the active site pocket (22). It
is thought that Pi is released from the back door (23), and it is
anticipated that a large conformational change occurs before Pi
release (21). Starting from theM.ADP.Pi state, actin binds strongly
to myosin, opening the backdoor, and swinging the converter/lever
arm, which then allows Pi to dissociate. Thus, it is possible that
binding of the GTD to the motor domain slows the movement of
the converter/lever arm, thus preventing Pi release.
The proposed model for inhibited myosin Va is reminiscent of
the inhibited structures of vertebrate smooth muscle myosin II (24,
25) and invertebrate striated muscle myosin II (26), in which the tip
of one motor domain binds to the converter region of the other.
Thus, it is plausible that the inhibition of the converter/lever-arm
movement is a general strategy for myosin motor proteins to
achieve the inhibited state.
Mechanism for Ca2-Dependent Regulation of Myosin Va. Micromo-
lar concentration of Ca2 (pCa6-pCa5) stimulates the ATPase
activity of myosin Va and induces an open conformation (5–8).
Thus, it is expected that activation is initiated by the binding of Ca2
to CaM, which is bound to the neck domain. The proposed model
for the interaction between the motor domain and the GTD
immediately suggests two mechanisms for Ca2-dependent regu-
lation of myosin Va.
One possible mechanism is that the C-terminal domain of the
CaM in IQ1 is part of or close to the GTD-binding pocket (Fig. 6),
and Ca2-induced conformational change of CaM in IQ1 may
prevent the interaction between the motor domain and the GTD.
This mechanism appears to be inconsistent with the report that the
light chain in the IQ1 of chicken myosin Va is LC-1sa but not CaM
(27). Coexpression of various light chains andCaMwith a truncated
chicken myosin Va containing motor domain and IQ1 showed that
the relative order of affinity for the IQ1 is as follows: LC-1sa 
LC-17b  CaM (27). However, the relatively low affinity between
CaMand IQ1 in the truncatedmyosinVadoes not necessarilymean
a low affinity between CaM and IQ1 in the intact neck having six
IQ motifs. It is known that the affinity of CaM for IQ motifs is
influenced by the light chain in the neighboring IQ motif (28). The
crystal structure of CaM bound to IQ1 and IQ2 of mouse myosin
Va shows that there are apolar interactions between CaMs in IQ1
and IQ2 (29). Thus, it is likely that interactions between the
adjacent CaMs change their affinity for IQ1 and IQ2 of myosin V
heavy chain. Indeed, a recent study showed that the light chain
bound to IQ1 of tissue-isolated chicken myosin Va is actually
CaM (30).
Alternatively, Ca2-induced activation is initiated from the CaM
in IQ2 and transduced to the CaM in IQ1 through interaction
CaM/IQ1
CaM/IQ2
GTD
Motor Domain
  R272
(K1706)
  K343
(K1779)
D136
Mg ADP BeFx
Fig. 6. Model for interaction between the GTD and the motor domain of
myosin Va in the postrigor conformation. The GTD-binding pocket consists of the
N-terminal domain (blue), converter (orange), and the CaM (cyan) in IQ1. Sub-
domain-II (yellow) of the GTD interacts with the motor domain. The distances
between the oxygen atom (O) of D136 in the motor domain and the nitrogen
atom (N) of K272 and the nitrogen atom (N) of R343 in Myo2p-GTD (homolog
residues of K1706 and K1779 in mouse myosin Va, respectively) are4 Å.
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between these CaMs as shown in the crystal structure of light
chain-binding domain of myosin V (29, 31). It appears that activa-
tion ofATPase activity ofmyosinVaby highCa2 is correlatedwith
Ca2-induced dissociation of CaM from a single specific IQ motif
(32). Several groups have identified the specific IQ motif to be IQ2
and proposed that myosin Va is regulated by Ca2 via the CaM in
IQ2 in a way similar to scallop myosin and smooth muscle myosin
(30, 33–35). Currently, there is no direct evidence to distinct these
two mechanisms and further experiments are required.
Materials and Methods
Proteins. Full-length mouse melanocyte-type myosin Va (M5Full) and myosin Va
HMM residues of M1-A1234 (M5HMM) were prepared as described in ref. 9. The
GST-GTD fusion protein comprised the C-terminal 410 residues of myosin Va,
encompassing the entire GTD, which was subcloned into pGEX-4T2 (Amersham)
from pFastHTb (Invitrogen) (9) by using BamH1 and XhoI sites, was expressed and
purified by standard techniques. The purified GST-GTD protein was dialyzed
against5mMTrisHCl (pH7.5at20°C),0.2MNaCl,and1mMDTToniceovernight.
The concentration of GST-GTD was measured by absorbance at 280 nm, using a
molar extinction coefficient of 71,990 litersmol1cm1.
Point mutations were introduced by Quikchange Site-directed mutagenesis
with Ultra High Fidelity Pfu (Stratagene) and standard molecular biological
techniques. cDNA derived from PCR were sequenced to confirm the presence of
intended mutations and absence of unintended mutation. Note that for easy
comparison with previous publications, we used the nucleotide number of
X57377, which contains exon-B and F but lacks exon-D. The melanocyte-type
myosin Va contains exon-D and -F but lacks exon-B (36). Other proteins and
reagents are as described in ref. 9.
ATPase Assay. The ATPase activity was measured in the presence of an ATP
regeneration system containing pyruvate kinase and phosphoenolpyruvate
(PEP). The amount of liberated pyruvate was detected by dinitrophenyl hydr-
azine. The ATPase activity for M5Full was measured in the presence of various
concentrations of actin in a solution containing 20 mM Mops-KOH (pH 7.0), 0.1 M
NaCl, 1 mM MgCl2, 1 mM DTT, 0.25 mg/ml BSA, 12 M calmodulin, 0.5 mM ATP,
2.5 mM PEP, 20 units/ml pyruvate kinase, 10–100 nM M5Full, 1 mM EGTA, and
various concentrations of actin at 25°C for EGTA conditions (in the absence of
Ca2). EGTA (1 mM) was replaced with 0.9 mM EGTA and 1 mM CaCl2 for pCa4
conditions (in the presence of Ca2). The ATPase activity of M5HMM in the
presence of GST-GTD was measured in EGTA conditions in a solution containing
20 mM Mops-KOH (pH 7.0), 0.1 M NaCl, 1 mM MgCl2, 1 mM DTT, 0.25 mg/ml BSA,
12 M calmodulin, 0.5 mM ATP, 2.5 mM PEP, 20 units/ml pyruvate kinase, 20–50
nM M5HMM, 40 M actin, 1 mM EGTA, and various concentrations of GST-GTD
at 25°C. The reaction was stopped at various times between 4 and 60 min by
adding 25 l of reaction solution to a well of 96-well plate (Flat Bottom) con-
taining 100l of 0.36 mM 2,4-dinitrophenyl hydrazine (Sigma–Aldrich) and 0.4 M
HCl.After incubationat37°Cfor15min,50lof2.5MNaOHand0.1MEDTAwere
added to each well, and the absorptions at 450 nm were recorded in a microplate
reader.
Calculation of Dissociation Constant (Kd) of GST-GTD and M5HMM. See SI
Materials and Methods.
Other Assays.Negative staining electron microscopy was performed as described
in ref. 9. The sedimentation coefficients of M5Full were measured by analytical
ultracentrifugation as described with minor modification (6). The purified M5Full
wasdialyzedagainst10mMMops-KOH(pH7.0),0.2MNaCl,1mMDTT,and1mM
EGTA on ice overnight. Just before running, MgCl2 was adjusted to 1 mM for
EGTA conditions; MgCl2 and CaCl2 were adjusted to 1 mM and 1.1 mM, respec-
tively, for the pCa4 conditions.
Model Building.The model of the head domain and the binding of the GTD to the
head domain were created by using Swiss PDB viewer software. The model of the
motor domain and the first two IQ motifs domain of myosin Va was created from
the motor domain from chicken myosin Va ADP.BeFx (1w7j.pdb) (13) and the first
two IQ motifs domain from mouse myosin Va (2ix7.pdb) (29) by superposing the
backbone of R767-I773. The model of the interaction between the head domain
and the GTD was created from the head domain of myosin Va (above) and the
Myo2p-GTD, the GTD of a yeast myosin V (2f6h.pdb) (14), by positioning the
oxygen atom (O) of D136 in myosin Va and nitrogen atom (N) of R272 and
nitrogen atom (N) of K343 in Myo2p-GTD (homologous to K1706 and K1779 of
mouse myosin Va, respectively) within a distance of4 Å and avoiding collision
with the N-terminal domain and converter domain.
ACKNOWLEDGMENTS. We thank Kimberley Crowley (University of Massachu-
setts Medical School) for technical assistance in analytical ultracentrifugation.
This work was supported by an American Heart Association Scientist Devel-
opment Grant (to X.-d.L.) and National Institutes of Health Grants AR41653,
AR048526, and DC006103 (to M.I.) and AR34711 (to R.C.).
1. Wu XS, Rao K, Zhang H, Wang F, Sellers JR, Matesic LE, Copeland NG, Jenkins NA,
Hammer JA, III (2002) Nat Cell Biol 4:271–278.
2. Wu X, Wang F, Rao K, Sellers JR, Hammer JA, III (2002) Mol Biol Cell 13:1735–1749.
3. Fukuda M, Kuroda TS (2004) J Cell Sci 117:583–591.
4. Li XD, Ikebe R, Ikebe M (2005) J Biol Chem 280:17815–17822.
5. Cheney RE, O’Shea MK, Heuser JE, Coelho MV, Wolenski JS, Espreafico EM, Forscher P,
Larson RE, Mooseker MS (1993) Cell 75:13–23.
6. Li XD, Mabuchi K, Ikebe R, Ikebe M (2004) BiochemBiophys Res Commun 315:538–545.
7. Wang F, Thirumurugan K, Stafford WF, Hammer JA, III, Knight PJ, Sellers JR (2004) J Biol
Chem 279:2333–2336.
8. Krementsov DN, Krementsova EB, Trybus KM (2004) J Cell Biol 164:877–886.
9. Li XD, Jung HS, Mabuchi K, Craig R, Ikebe M (2006) J Biol Chem 281:21789–21798.
10. Thirumurugan K, Sakamoto T, Hammer JA, III, Sellers JR, Knight PJ (2006) Nature
442:212–215.
11. Liu J, Taylor DW, Krementsova EB, Trybus KM, Taylor KA (2006) Nature 442:208–211.
12. Coureux PD, Wells AL, Menetrey J, Yengo CM, Morris CA, Sweeney HL, Houdusse A
(2003) Nature 425:419–423.
13. Coureux PD, Sweeney HL, Houdusse A (2004) EMBO J 23:4527–4537.
14. Pashkova N, Jin Y, Ramaswamy S, Weisman LS (2006) EMBO J 25:693–700.
15. Dominguez R, Freyzon Y, Trybus KM, Cohen C (1998) Cell 94:559–571.
16. Houdusse A, Szent-Gyorgyi AG, Cohen C (2000) Proc Natl Acad Sci USA 97:11238–11243.
17. Smith CA, Rayment I (1996) Biochemistry 35:5404–5417.
18. Fisher AJ, Smith CA, Thoden JB, Smith R, Sutoh K, Holden HM, Rayment I (1995)
Biochemistry 34:8960–8972.
19. Fischer S, Windshugel B, Horak D, Holmes KC, Smith JC (2005) Proc Natl Acad Sci USA
102:6873–6878.
20. Malnasi-Csizmadia A, Toth J, Pearson DS, Hetenyi C, Nyitray L, Geeves MA, Bagshaw CR,
Kovacs M (2007) J Biol Chem 282:17658–17664.
21. Geeves MA, Holmes KC (1999) Annu Rev Biochem 68:687–728.
22. Sato O, Li XD, Ikebe M (2007) J Biol Chem 282:13228–13239.
23. Yount RG, Lawson D, Rayment I (1995) Biophys J 68:44S–47S; discussion 47S–49S.
24. Wendt T, Taylor D, Trybus KM, Taylor K (2001) Proc Natl Acad Sci USA 98:4361–4366.
25. Burgess SA, Yu S, Walker ML, Hawkins RJ, Chalovich JM, Knight PJ (2007) J Mol Biol
312:1165–1178.
26. Woodhead JL, Zhao FQ, Craig R, Egelman EH, Alamo L, Padron R (2005) Nature
436:1195–1199.
27. De La Cruz EM, Wells AL, Sweeney HL, Ostap EM (2000) Biochemistry 39:14196–14202.
28. Martin SR, Bayley PM (2002) Protein Sci 11:2909–2923.
29. Houdusse A, Gaucher JF, Krementsova E, Mui S, Trybus KM, Cohen C (2006) Proc Natl
Acad Sci USA 103:19326–19331.
30. Koide H, Kinoshita T, Tanaka Y, Tanaka S, Nagura N, Meyer zu Horste G, Miyagi A, Ando
T (2006) Biochemistry 45:11598–11604.
31. Terrak M, Rebowski G, Lu RC, Grabarek Z, Dominguez R (2005) Proc Natl Acad Sci USA
102:12718–12723.
32. Nascimento AA, Cheney RE, Tauhata SB, Larson RE, Mooseker MS (1996) J Biol Chem
271:17561–17569.
33. Homma K, Saito J, Ikebe R, Ikebe M (2000) J Biol Chem 275:34766 –34771.
34. Trybus KM, Krementsova E, Freyzon Y (1999) J Biol Chem 274:27448–27456.
35. Trybus KM, Gushchin MI, Lui H, Hazelwood L, Krementsova EB, Volkmann N, Hanein D
(2007) J Biol Chem 282:23316–23325.
36. Seperack PK, Mercer JA, Strobel MC, Copeland NG, Jenkins NA (1995) EMBO J 14:2326–
2332.
Li et al. PNAS  January 29, 2008  vol. 105  no. 4  1145
BI
O
CH
EM
IS
TR
Y
